We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Nova Biomedical

Nova is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers... read more Featured Products: More products

Download Mobile App




Nova Biomedical Launches New BioProfile FLEX2 On-Line Autosampler

By LabMedica International staff writers
Posted on 03 Jan 2020
Print article
Image: BioProfile FLEX2 On-Line Autosampler (Photo courtesy of Nova Biomedical)
Image: BioProfile FLEX2 On-Line Autosampler (Photo courtesy of Nova Biomedical)
Nova Biomedical (Waltham, MA, USA) has launched the BioProfile FLEX2 On-Line Autosampler (OLS), a modular system that connects as many as 10 bioreactors to one FLEX2 analyzer for up to three weeks of walkaway, automated sampling, analysis, and feedback control of key cell culture analytes. The FLEX2 measures up to 16 tests, including pH, gases, metabolites, osmolality, cell density, and cell viability.

Nova develops and manufactures state-of-the-art, whole blood point-of-care and critical care analyzers, as well as the most advanced instruments for cell culture monitoring in the biotechnology market. Nova’s biosensor technology is incorporated in its products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers for the rapid measurement of over 20 analytes. Nova’s biotechnology-specific BioProfile line has pioneered comprehensive cell culture testing, providing over 16 critical cell culture tests with 12 unique instrument offerings for a broad range of cell culture applications.

Nova’s FLEX2 combines its MicroSensor Card chemistry technology with optical measurements and freezing point osmometry to offer an automated and comprehensive cell culture analyzer that eliminates chemistry sensor maintenance, increases analyzer speed, and reduces sample volume. With the OLS, FLEX2 uses a small sample volume of 5.6 mL for the 16-test assay to allow frequent sampling for this detailed look at culture performance. Up to 24 samples per day for each of 10 bioreactors can be analyzed in as fast as six minutes, with proven comparability to manual sampling. The OLS provides automated sampling, analysis, and feedback control of 10 bioreactors in as fast as one hour for chemistry results, with only 20 minutes needed for setup. The ability of OLS and FLEX2 to provide unaided capture of key cell culture attributes across 10 bioreactors saves hours of scientists’ time versus manual sampling and analysis, and eliminates after-hours cell culture monitoring.

“We are excited to launch the next addition to the BioProfile FLEX2 platform with the On-Line Autosampler. FLEX2 OLS represents the latest in cell culture automation technology and further demonstrates Nova’s leadership and history of innovation,” said Matt McRae, sales product line manager at Nova.

Related Links:
Nova Biomedical

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.